{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 4.715641, "regularMarketPrice": 0.5929, "exchange": "NCM", "shortName": "NeuroBo Pharmaceuticals, Inc.", "longName": "NeuroBo Pharmaceuticals, Inc.", "messageBoardId": "finmb_630763379", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "bookValue": 0.855, "fiftyDayAverage": 0.68688, "fiftyDayAverageChange": -0.093980014, "fiftyDayAverageChangePercent": -0.1368216, "twoHundredDayAverage": 4.83982, "twoHundredDayAverageChange": -4.24692, "twoHundredDayAverageChangePercent": -0.87749547, "marketCap": 16813754, "forwardPE": -0.6444565, "priceToBook": 0.6934503, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "earningsTimestamp": 1683921600, "earningsTimestampStart": 1691697600, "earningsTimestampEnd": 1692043200, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -15.09, "epsForward": -0.92, "epsCurrentYear": -0.98, "priceEpsCurrentYear": -0.60499996, "sharesOutstanding": 18972000, "firstTradeDateMilliseconds": 1470403800000, "priceHint": 4, "regularMarketChange": 0.02669996, "regularMarketTime": 1684180786, "regularMarketDayHigh": 0.5937, "regularMarketDayRange": "0.57 - 0.5937", "regularMarketDayLow": 0.57, "regularMarketVolume": 155149, "regularMarketPreviousClose": 0.5662, "bid": 0.0, "ask": 0.0, "bidSize": 10, "askSize": 11, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 0.59, "averageDailyVolume3Month": 504755, "averageDailyVolume10Day": 434230, "fiftyTwoWeekLowChange": 0.04189998, "fiftyTwoWeekLowChangePercent": 0.07604352, "fiftyTwoWeekRange": "0.551 - 63.85", "fiftyTwoWeekHighChange": -63.2571, "fiftyTwoWeekHighChangePercent": -0.9907142, "fiftyTwoWeekLow": 0.551, "fiftyTwoWeekHigh": 63.85, "dividendDate": 1577750400, "marketState": "PRE", "displayName": "NeuroBo Pharmaceuticals", "symbol": "NRBO"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "200 Berkeley Street", "address2": "Office 19th Floor", "city": "Boston", "state": "MA", "zip": "02116", "country": "United States", "phone": "857 702 9600", "website": "https://www.neurobopharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 2, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joseph  Hooker", "title": "Interim CEO & Pres", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}